Purpose: evaluation of the role of the Ex-PRESS device implantation in the management of pseudophakic glaucoma. Design: non-comparative case series study. Patients and methods: 6 eyes with pseudophakic glaucoma scheduled to undergo Ex-PRESS glaucoma filtration device. Each study patient underwent a complete ophthalmic examination preoperatively including full clinical history taking, VA measurement, autorefraction examination, slit lamp biomicroscopy of the anterior segment, IOP measurement using Goldmann applanation tonometer, gonioscopic examination to evaluate of the angle of AC, and ophthalmoscopy of the posterior segment using a direct ophthalmoscopy. All the patients were subjected to functional and structural evaluation by SAP (HFA 745i) for central 30-2 threshold test, endothelial cell evaluation by non-contact specular microscopy (Topcon specular microscope; SP-1P Version 1.20) for endothelial cell count and OCT scans (Topcon 3D OCT-2000) for peripapillary RNFL thickness measurements, ONH analysis and GCA. All patients included were having pseudophakic OAG. Patients were excluded if they were under 18 years old. All eyes underwent Ex-PRESS device implantation performed by the same surgeon for consistency, using the standardized technique for the procedure. A complete ophthalmologic follow-up examination included IOP measurement using Goldmann applanation tonometry, number of drugs required to attain IOP control and any associated complications was carried out postoperatively at the 1st and 3rd days, the end of 1st week, every month till the end of the 6th month and the end of 1st year. Best-corrected visual acuity (BCVA) was tested using Snellen chart, which was converted to LogMAR for statistical analysis. Criteria for success were defined as follows; Absolute success: IOP ≤21 mmHg without any medication, qualified success: IOP ≤21 mmHg with ocular hypotensive medications. VF test with SAP, specular microscopy and ONH analysis and GCA assessed with OCT were carried out one year postoperatively. Results: There were 4 eyes (80%) showed complete success (IOP <21mmHg without treatment) and 1 eyes (20%) showed qualified success (IOP <21 mmHg with anti-glaucoma medical treatment). There is a statistically significant reduction in IOP 1, 3, 6 months and one year postoperatively (P<0.001) with the most reduction in IOP observed at 6 months after surgery due to controlling all cases with IOP >21 mmHg using anti-glaucoma medications by this time.
Introduction:
Glaucoma in pseudophakic eyes is not uncommon. Pseudophakia by itself does not cause ocular hypertension. Pseudophakic glaucoma should be defined as glaucoma that would not be present in an eye if it were not pseudophakic.
(1) Clear corneal phacoemulsification (CCP) is associated with significant and sustained reduction in IOP in both normal subjects and patients with POAG.
(2-3) However; The implantation of an intraocular lens (IOL) after phacoemulsification may determine the appearance of some additional mechanisms for secondary glaucoma such as pupillary block, inflammation, haemorrhage, and pigment dispersion. (4) The pseudophakic glaucoma may occur immediately after the implantation or later during the postoperative course, including both the OAG and ACG. One of the surgical treatments for pseudohakic glaucoma is glaucoma drainage device (GDD) implantation such as Ex-PRESS device.
(5) The Ex-PRESS miniature glaucoma implant (Alcon Laboratories Inc., Fort Worth, TX) is a biocompatible, non-valved stainless steel tube. The Ex-PRESS is currently implanted under a partial thickness sclera flap, as first suggested by Dahan and Carmicheal. (6) the procedure is similar to standard trabeculectomy, and includes creation of scleral flap and a conjunctival filtration bleb, but no peripheral iridectomy is required. Herein, we evaluate the role of the Ex-PRESS device implantation in the management of pseudophakic glaucoma.
Patients and methods:
This is a non-comparative case series study of 6 eyes with pseudophakic glaucoma that were scheduled to undergo Ex-PRESS glaucoma filtration device. All patients' data were collected between November 2016 and July 2018(the patients are operated between November 2016 to April 2017 and then followed up for one year) at Ophthalmology department -Sohag University hospital. The research adhered to the tenets of the Declaration of Helsinki. Written informed consent was taken from each patient. Each study patient underwent a complete ophthalmic examination preoperatively including full clinical history taking, VA measurement, autorefraction examination, slit lamp biomicroscopy of the anterior segment, IOP measurement using Goldmann applanation tonometer, gonioscopic examination to evaluate of the angle of AC, and ophthalmoscopy of the posterior segment using a direct ophthalmoscopy. All the patients were subjected to functional and structural evaluation by SAP (HFA 745i) Ex-PRESS device implantation performed by the same surgeon for consistency, using the standardized technique for the procedure. All the procedures were performed in the superior conjunctival area. After retrobulbar local anesthesia, superior rectus bridle suture was taken. A fornix-based conjunctival flap was created with a relaxing incision on one side. Next, a 50% thickness rectangular scleral flap (5x5mm) was constructed and advanced anteriorly into the clear cornea using Alcon crescent knife (Saint Crescent, angled, bevel up). Paracentesis was done temporally using a 20G micro-vitreoretinal (MVR) blade. As the scleral flap was lifted, care was taken to identify the center of the "blue line" adjacent to the clear cornea, which corresponds to the location of the TM. A 25G needle (Ex-PRESS entry system) was inserted into the AC through the center of the "blue line" at an angle parallel to the iris plane to create a path for the Ex-PRESS (model P-50) and then removed gently to avoid lateral movement that may extend the channel and cause aqueous humor to leak around the shunt. The Ex-PRESS shunt is preloaded on an injector. The shunt is introduced into the AC exclusively through the ostium created by the needle and released by applying pressure to the shaft of the inserter. The tip of the device was confirmed to be in the AC in the iris plane away from the cornea and without any iris obstruction. The scleral flap is then sutured with interrupted 10-0 Nylon. Two to three sutures were typically required with the tightness adjusted depending on the resultant flow during inflation of the AC with balanced salt solution using a 27G needle through the temporal paracentesis to restrict flow to a "slow trickle" while the AC remains well maintained. Finally, the conjunctival incision was closed water tight fashion using an interrupted 10-0 Nylon. We confirmed that there was no leakage from the blebs. All patients received similar postoperative topical medications: 0.5% moxifloxacin five times daily for 3 weeks and 0.1% prednisolone acetate five times daily for 3 week without tapering after operation.
Follow up:
A complete ophthalmologic follow-up examination included IOP measurement using Goldmann applanation tonometry, number of drugs required to attain IOP control and any associated complications was carried out postoperatively at the 1st and 3rd days, the end of 1st week, every month till the end of the 6th month and the end of 1st year. Best-corrected visual acuity (BCVA) was tested using Snellen chart, which was converted to LogMAR for statistical analysis. Criteria for success were defined as follows; Absolute success: IOP ≤21 mmHg without any medication, qualified success: IOP ≤21 mmHg with ocular hypotensive medications. VF test with SAP, specular microscopy and ONH analysis and GCA assessed with OCT were carried out one year postoperatively.
Results:
One case showed migration and extrusion of the device four months postoperatively, which was excluded from the results (Figure 1 ). 
Discussion:
Glaucoma is the leading cause of irreversible blindness worldwide and represents a significant public health concern.
(7) The Ex-Press GDD is a new method for standardizing trabeculectomy with outcomes quite similar to trabeculectomy reported in the literature. previous study by Takihara (8) showed that the rate of failure of trabeculectomy with MMC among patients with OAG was higher in pseudophakic eyes after phacoemulsification than in phakic eyes. Some studies (9) (10) 
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Scar formation in the conjunctiva of patients with glaucoma. In our study, the complete and qualified success rates were 80% and 20% respectively after 1 year of Ex-PRESS implantation. A recent retrospective study evaluated the surgical prognosis of trabeculectomy in 51 pseudophakic eyes after phacoemulsification among patients with OAG. (11) In that study, the probability of success at 1 year after trabeculectomy in pseudophakic eyes was 78.6% for IOP of less than 21 mmHg. The pathomechanism for failure of trabeculectomy in pseudophakic eyes is not fully understood. (12) https://jamanetwork.com/journals/jamao phthalmology/fullar cle/1774027 -eoi130184r15 Alterations in the nature of the AH may contribute to failure of trabeculectomy. Intraocular surgery causes ocular inflammation and breakdown of the blood-aqueous barrier, which may cause bleb failure after trabeculectomy.
A high concentration of inflammatory cytokines has been shown in the AH of pseudophakic eyes with glaucoma. (14) In our study, the number of antiglaucoma medications taken postoperatively (0.92+1.08) was significantly lower than number of medications taken preoperatively (3.56+0.51) ( P <0.001). In previous study by Liu et al, (15) the number of glaucoma medications taken postoperatively was lower than the number of glaucoma medications taken pre-operatively (0.94 ± 0.96 vs. 1.18 ± 1.38). In a study comparing Ex-PRESS to trabeculectomy in an African origin population, (16) Wagschal et al (20) found that VA in patients treated with the Ex-PRESS implant did not differ significantly from baseline by 1 month postoperation ( P =0.17), and remained stable for all subsequent visits. In another prospective randomized trial by Beltran-Agullo et al, (21) by month 1, VA in the Ex-PRESS group was no longer significantly different from baseline (P=0.23) and remained stable throughout 6 months of follow-up. Regarding VF changes, our study showed improvement of global indices (MD & PSD). MD improved from (-21.12+8.71) prepoeratively to (-18.82+8.41) one year postoperatively (P<0.001). Also, PSD showed improvement from (6.7+2.66) preoperatively to (6.12+2.76) one year postoperatively ( P =0.002). However, GSS2, a parameter evaluate both MD and PSD simultaneously, showed no difference pre-and post-operatively (P=0.327). It has been shown previously (22) (23) that light sensitivity may increase diffusely across the VF when IOP is surgically reduced.
In addition, local improvement in the VF was also found. One study suggested that perimetric improvement after initiation of therapy occurs more often in younger individuals, (25) a finding we could not confirm because no patient younger than 40 years of age was included in our study. It also has been reported that improvement occurs mostly in eyes with early VF loss, (26) Hence the importance of control groups when studying treatment effects on a disease like glaucoma, when the outcome variable is derived from a psychophysical test whose results are known to be affected by perimetric learning effect. (27) (28) Regarding the OCT parameters, our results showed increase in thickness of both RNFL and GCC. RNFL thickness increased from (56.80+17.49) um preoperatively to (62.80+18.91) um one year postoperatively ( P <0.001). Moreover, GCC thickness increased from (64.84+14.00) um preoperatively to (72.00+16.73) um 1 year postopertively (P<0.001). In a study by Sarkar, (29) there was significant RNFL thickness changes found with significant reduction of IOP. The physiologic basis of the improvement in RNFL thickness with IOP reduction is not clear. It has been suggested that IOP reduction results in less posterior bowing of the lamina cribrosa. (30) (31) The clinical implications of the RNFL thickness improvement are unclear, although previous studies have shown that there may be an associated improvement of visual function that corresponds to this improvement (32) (33) and similar findings have been reported by Lesk et al. (34) Ali Aydin et al (35) found a significant increase in overall mean peripapillary RNFL thickness after surgery as determined by OCT ( P <0.0001). 28 (73.7%) of 38 eyes had an IOP reduction >30%. The mean RNFL thickness increase (0.5 um/mmHg decrease of IOP) was significantly correlated with the IOP reduction (r =-0.41; P=0.03).
The possible explanation is that the increase of RNFL thickness may reflect the recovery of the compressed RNFL, which regains its original shape because of the IOP reduction. As compression on the axons is relieved with IOP reduction, the axons may recover their normal shape and size, with resultant increase in RNFL thickness. In contrast, Chang et al (36) 
